| Amy Suzanne Pullen, PHARMD | |
|
500 W Fort St, Boise, ID 83702-4501 | |
| (208) 422-1000 | |
| Not Available |
| Full Name | Amy Suzanne Pullen |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 500 W Fort St, Boise, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205116266 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 26023744A (Indiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Amy Suzanne Pullen, PHARMD 500 W Fort St, Boise, ID 83702-4501 Ph: () - | Amy Suzanne Pullen, PHARMD 500 W Fort St, Boise, ID 83702-4501 Ph: (208) 422-1000 |
News Archive
From 11-14 March 2015, Tropical Cyclone Pam, with winds of up to Category 5, hit the Solomon Islands and Vanuatu. At the same time, the Cyclone caused high waves to crash over atoll islands in Kiribati and the Solomon Islands. The super cyclone is one of the worst natural disasters in South Pacific history.
N30 Pharmaceuticals, Inc., a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, announced today the presentation of key preclinical data for its novel inhibitors of S-nitrosoglutathione reductase.
Michigan State University researchers used an old-fashioned neurobiology technique to explore new avenues for treatments to reverse a late-onset neurodegenerative disease that robs men of the capacity to walk, run, chew and swallow.
Boston Scientific Corporation today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the performance of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients. Results demonstrated that despite the known increased risk of restenosis for diabetics versus non-diabetics in patients undergoing coronary revascularization, the TAXUS Element Stent had comparable levels of target lesion revascularization (TLR) and late loss in both diabetic and non-diabetic patients.
TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.
› Verified 9 days ago
Eleanor I Evans, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5005 W Overland Rd, Boise, ID 83705 Phone: 208-389-1448 Fax: 208-389-1458 | |
Ms. Fatima Walizada, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5005 W Overland Rd, Boise, ID 83705 Phone: 208-389-1448 | |
David Lyn Harrison, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9196 W Emerald St, Suite 110, Boise, ID 83704 Phone: 208-323-1259 Fax: 208-323-5666 | |
Mary Gobeille, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5230 W Franklin Rd, Boise, ID 83705 Phone: 208-429-6433 | |
Megan B Seewald, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3233 N Cole Rd, Boise, ID 83704 Phone: 208-501-7032 Fax: 208-501-7026 | |
Dr. Christopher K Johnson, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3232 Elder Street, Boise, ID 83705 Phone: 208-364-1829 Fax: 180-032-7554 | |
Dr. Catherine M Oliphant, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 E Jefferson St, Suite 201, Boise, ID 83712 Phone: 208-381-4146 Fax: 208-381-1665 |